Literature DB >> 12684257

Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP.

Jesper Mosolff Mathiesen1, Nannette Svendsen, Hans Bräuner-Osborne, Christian Thomsen, M Teresa Ramirez.   

Abstract

We have identified 2-methyl-6-(2-phenylethenyl)pyridine (SIB-1893) and 2-methyl-6-phenylethynyl pyridine hydrochloride (MPEP) as positive allosteric modulators for the hmGluR4. SIB-1893 and MPEP enhanced the potency and efficacy of L-2-amino-4-phophonobutyrate (L-AP4) in guanosine 5'-O-(3-[(35)S]thiotriphosphate ([(35)S]GTPgammaS) binding and efficacy in cAMP studies. These effects were fully blocked by the mGluR4 competitive antagonist (RS)-alpha-cyclopropyl-4-phosphonophenylglycine (CPPG), indicating a dependency on receptor activation. Although SIB-1893 and MPEP had no effects alone in GTPgammaS binding, effects were observed in the cell-based cAMP assay due to media-derived activation as indicated by CPPG inhibition. Positive modulation of the mGluR4 was a receptor-specific effect since SIB-1893 and MPEP had neither effects on mGluR2-expressing cells nor on the parent BHK cell line. In [(3)H]L-AP4 binding, a two-fold decrease in K(D) but not in B(max) was observed with 100 micro M SIB-1893, whereas MPEP affected neither parameter. Finally, SIB-1893 and MPEP failed to displace [(3)H]L-AP4 binding. Taken together, these data identify positive allosteric modulators for the hmGluR4.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684257      PMCID: PMC1573757          DOI: 10.1038/sj.bjp.0705159

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation.

Authors:  D A Hall
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

Review 2.  Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives.

Authors:  Fabrizio Gasparini; Rainer Kuhn; Jean-Philippe Pin
Journal:  Curr Opin Pharmacol       Date:  2002-02       Impact factor: 5.547

3.  Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site.

Authors:  F Knoflach; V Mutel; S Jolidon; J N Kew; P Malherbe; E Vieira; J Wichmann; J A Kemp
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

4.  Effect of the umami peptides on the ligand binding and function of rat mGlu4a receptor might implicate this receptor in the monosodium glutamate taste transduction.

Authors:  K Monastyrskaia; K Lundstrom; D Plahl; G Acuna; C Schweitzer; P Malherbe; V Mutel
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

5.  Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism.

Authors:  D M O'Leary; V Movsesyan; S Vicini; A I Faden
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

6.  Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501.

Authors:  S Urwyler; J Mosbacher; K Lingenhoehl; J Heid; K Hofstetter; W Froestl; B Bettler; K Kaupmann
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

7.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.

Authors:  F Gasparini; K Lingenhöhl; N Stoehr; P J Flor; M Heinrich; I Vranesic; M Biollaz; H Allgeier; R Heckendorn; S Urwyler; M A Varney; E C Johnson; S D Hess; S P Rao; A I Sacaan; E M Santori; G Veliçelebi; R Kuhn
Journal:  Neuropharmacology       Date:  1999-10       Impact factor: 5.250

8.  Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective.

Authors:  V Bruno; I Ksiazek; G Battaglia; S Lukic; T Leonhardt; D Sauer; F Gasparini; R Kuhn; F Nicoletti; P J Flor
Journal:  Neuropharmacology       Date:  2000-09       Impact factor: 5.250

9.  Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor.

Authors:  N Kunishima; Y Shimada; Y Tsuji; T Sato; M Yamamoto; T Kumasaka; S Nakanishi; H Jingami; K Morikawa
Journal:  Nature       Date:  2000-10-26       Impact factor: 49.962

10.  mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors.

Authors:  V A Movsesyan; D M O'Leary; L Fan; W Bao; P G Mullins; S M Knoblach; A I Faden
Journal:  J Pharmacol Exp Ther       Date:  2001-01       Impact factor: 4.030

View more
  55 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons.

Authors:  Christine DeLorenzo; Matthew S Milak; Kathleen G Brennan; J S Dileep Kumar; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-29       Impact factor: 9.236

3.  Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats.

Authors:  Nathalie Breysse; Marianne Amalric; Pascal Salin
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

4.  The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor.

Authors:  Virginie Binet; Carole Brajon; Laurent Le Corre; Francine Acher; Jean-Philippe Pin; Laurent Prézeau
Journal:  J Biol Chem       Date:  2004-05-04       Impact factor: 5.157

Review 5.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

Review 6.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

7.  Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators.

Authors:  Ralf Mueller; Eric S Dawson; Colleen M Niswender; Mariusz Butkiewicz; Corey R Hopkins; C David Weaver; Craig W Lindsley; P Jeffrey Conn; Jens Meiler
Journal:  J Mol Model       Date:  2012-05-17       Impact factor: 1.810

8.  The metabotropic glutamate receptor 4 is internalized and desensitized upon protein kinase C activation.

Authors:  Jesper Mosolff Mathiesen; M Teresa Ramirez
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

9.  Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.

Authors:  Michael J Marino; David L Williams; Julie A O'Brien; Ornella Valenti; Terrence P McDonald; Michelle K Clements; Ruiping Wang; Anthony G DiLella; J Fred Hess; Gene G Kinney; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205

10.  Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.

Authors:  Colleen M Niswender; Kari A Johnson; C David Weaver; Carrie K Jones; Zixiu Xiang; Qingwei Luo; Alice L Rodriguez; Joy E Marlo; Tomas de Paulis; Analisa D Thompson; Emily L Days; Tasha Nalywajko; Cheryl A Austin; Michael Baxter Williams; Jennifer E Ayala; Richard Williams; Craig W Lindsley; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2008-07-29       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.